- CATT study two-year results
Published the two-year results of the CATT (Comparison of Age-related Macular Degeneration Treatments Trials), the first prospective randomised trial comparing Ranibizumab (Lucentis) and Bevacizumab (Avastin) in the treatment of neovascular AMD. These results confirmed the substantial equivalence between the two drugs in terms of their effects on visual acuity. As-needed' administration was found to induce a lower increase in visual acuity, whether taken from the start or after 1 year of monthly dosing. There were no differences between the two drugs in terms of mortality rates or arterio-thrombotic events. The significance of the higher rates of adverse effects in the case of bevacizumab is uncertain due to the lack of specificity for conditions associated with VEGF inhibition. Read the original published article online on Ophthalmology on 30 April 2012.
- CATT study one-year results
I One-year data from the CATT (Comparison of AMD Treatments Trial) showed that the two drugs were essentially equivalent in inducing an improvement in visual acuity, with dosing related to actual clinical conditions proving more effective than monthly dosing. Read the original article published in New England Journal of Medicine of 19 May 2011.
Dr. Carmelo Chines
Direttore responsabile
English 
Italian